Today, July 25, would be the 104th birthday of Lionel Terray. The celebrated French alpinist climbed routes from the Alps to the Himalaya to the Andes, and also wrote one of the all-time great ...

LOS ANGELES, November 17, 2025--(BUSINESS WIRE)--Terray Therapeutics, an AI-native, chemistry-first, biotech today announced its AI and experimental platform, EMMI, and the introduction of advanced ...

Dr. Young brings more than 30 years of drug discovery leadership and expertise, as Terray’s AI-driven internal and partnered programs continue to accelerate toward patients in need. LOS ANGELES, ...

Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A financing will ...

Success demonstrates the power of EMMI, Terray’s proprietary AI platform integrated with its rapidly expanding 13B+ target-ligand binding database and highly automated lab Terray Therapeutics ...

LOS ANGELES--(BUSINESS WIRE)--Terray Therapeutics today announced the appointment of industry veteran Elliott Levy, MD, to the company's Scientific Advisory Board. Terray is a biotechnology company ...

-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- -- Gilead Has Exclusive Option to Develop and ...

Gilead Sciences (NASDAQ:GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small molecule therapeutics across multiple targets utilizing Terray’s ...

Terray Therapeutics has emerged with $60 million in series A funding and a mission to turbocharge drug discovery using artificial intelligence and nanotechnology. Founded in 2018, Terray is developing ...